Menopause and Mental Health: Why This Phase Can Feel Like a Mental Health Crisis – and What Actually Helps

Of all the symptoms of menopause, the psychological ones are perhaps the most surprising, the most distressing, and the most commonly misidentified. Women who have never had anxiety find themselves overwhelmed by it. Women with no history of depression develop it for the first time in their 40s. Women describe feeling completely unlike themselves – emotionally labile, irritable, unable to concentrate, bereft of the mental clarity they’ve had their whole adult lives.

These are not personality changes. They are not signs of weakness or inability to cope. They are neurobiological consequences of hormonal transition that are well-documented, well-understood mechanistically, and in most cases, effectively treatable.

The problem is that they are still too often treated as primary psychiatric conditions – with antidepressants prescribed before anyone asks about menstrual history – rather than as hormonal symptoms that may resolve with hormonal treatment.

If you are in crisis or experiencing thoughts of self-harm, please seek help immediately from a mental health professional or emergency services.

The Scale of the Problem

The statistics are significant. Research consistently finds:

• The risk of depression is 2-4 times higher during perimenopause than in premenopausal years
• Anxiety affects approximately 51% of perimenopausal women
• Women are more likely to present to mental health services for the first time during perimenopause than at any other life stage
• The menopause transition is one of the two peak periods for new-onset depression in women (the other is the postpartum period)
• Women with a prior history of depression, PMS, PMDD, or postnatal depression are significantly more vulnerable

Yet surveys of women consistently show that mental health symptoms are the least expected and most distressing aspect of menopause – and the symptoms that most delay diagnosis, because neither the women experiencing them nor the healthcare providers seeing them connect them to hormonal transition.

Why Menopause Affects Mental Health: The Biology

The connection between oestrogen and mental health is not a modern discovery – it has been studied for decades. What’s changed is the depth of mechanistic understanding.

Oestrogen and Neurotransmitters

Oestrogen has direct effects on the synthesis, release, receptor sensitivity, and reuptake of multiple neurotransmitters involved in mood regulation:

Serotonin: Oestrogen upregulates serotonin synthesis, increases serotonin receptor sensitivity, and inhibits serotonin reuptake – effects that mirror those of SSRI antidepressants. When oestrogen falls, serotonergic signalling is reduced. This is why SSRIs that would have had no effect in reproductive years may suddenly become relevant at perimenopause – and conversely, why oestrogen therapy has antidepressant-like effects in perimenopausal depression.

GABA: Oestrogen modulates GABA-A receptor sensitivity. GABA is the brain’s primary inhibitory neurotransmitter – essentially the “calm” system. Progesterone metabolites (particularly allopregnanolone) are potent positive modulators of GABA-A receptors. When progesterone becomes erratic and then disappears, this GABAergic calming effect is lost. This is particularly relevant to anxiety – reduced GABAergic tone produces heightened anxiety, hypervigilance, and reduced stress resilience.

Dopamine: Oestrogen modulates dopaminergic reward circuits and motivation pathways. Declining oestrogen reduces dopaminergic activity in these circuits, contributing to anhedonia (reduced ability to feel pleasure), reduced motivation, and fatigue.

Norepinephrine: The noradrenergic system is involved in arousal, alertness, and stress response. Oestrogen modulates this system; its decline contributes to altered arousal patterns and stress reactivity.

The Hypothalamic-Pituitary-Adrenal (HPA) Axis

Oestrogen modulates the HPA axis – the body’s stress response system. During perimenopause, HPA axis regulation becomes dysregulated: the stress response becomes exaggerated, cortisol recovery after stress takes longer, and stress resilience is reduced. Women describe being overwhelmed by situations they previously handled without difficulty – this is not a failure of character but a reflection of altered neuroendocrine stress regulation.

Neuroinflammation

Oestrogen has anti-inflammatory effects in the brain. As it declines, neuroinflammatory signalling increases – and neuroinflammation is increasingly recognised as a driver of depression and anxiety. The same inflammatory cytokines elevated in depression (IL-6, TNF-α, CRP) are elevated in the menopausal transition.

Sleep Deprivation as an Amplifier

Night sweats cause repeated awakenings. Sleep deprivation independently causes depressed mood, anxiety, irritability, impaired concentration, reduced emotional regulation, and heightened pain sensitivity. In perimenopause, poor sleep is both a symptom and a driver of other symptoms – creating a self-reinforcing cycle where hormonal disruption impairs sleep, which worsens mood, which increases anxiety, which further disrupts sleep.

The Tryptophan-Kynurenine Pathway

When oestrogen is present, dietary tryptophan is preferentially converted to serotonin. When oestrogen declines and neuroinflammation increases, tryptophan is redirected down the kynurenine pathway, producing neurotoxic metabolites (quinolinic acid) and less serotonin. This is a direct biochemical mechanism connecting oestrogen deficiency to reduced serotonin availability and increased neurotoxicity.

What Perimenopausal Mental Health Symptoms Look Like

Anxiety

Perimenopausal anxiety often has a distinctive quality that women find difficult to describe. It is frequently:

• Physical: Racing heart, chest tightness, breathing difficulties, shakiness – the somatic components of anxiety are often prominent
• Nocturnal: Waking at 3-4am with racing thoughts and difficulty returning to sleep
• Unprovoked: Arising without clear external triggers, as waves of inexplicable anxiety or dread
• New: In women who have never been anxious before
• Associated with palpitations: The autonomic changes of perimenopause produce palpitations that amplify anxiety

This anxiety is frequently misdiagnosed as generalised anxiety disorder, panic disorder, or cardiac arrhythmia without the hormonal context being recognised.

Depression

Perimenopausal depression may differ from classical depression in several ways:

• Irritability predominates over sadness in many women – disproportionate, often surprising anger and low frustration tolerance
• Mood reactivity: Mood may improve temporarily in response to positive events (more like the atypical pattern) rather than being fixed
• Somatic symptoms: Physical symptoms (joint pain, fatigue, headaches) are prominent
• Cognitive symptoms: Brain fog and memory difficulties are significant features

In some women, the depression is severe – including suicidal ideation. The perimenopause is a high-risk period for suicide in women, and this risk is underrecognised.

Cognitive Symptoms (Brain Fog)

The “brain fog” of perimenopause is one of the most distressing symptoms for many women, particularly those in professional roles:

• Difficulty finding words (tip-of-tongue phenomenon)
• Short-term memory lapses
• Reduced ability to multitask
• Slowed processing speed
• Difficulty concentrating for sustained periods

Research confirms that these are real, measurable cognitive changes – not just subjective perception. Verbal memory and processing speed are particularly affected. These changes are largely reversible – studies show cognitive function returns to baseline after the transition.

Emotional Dysregulation

Many women describe an inability to regulate emotional responses that were previously easily managed:

• Crying at things that wouldn’t previously have affected them
• Disproportionate anger or irritability
• Feeling emotionally raw or oversensitive
• Rapid mood shifts within a day

Who Is Most Vulnerable

Prior depression or anxiety: The strongest predictor of perimenopausal mental health difficulties is prior history. Women who have experienced depression, anxiety, PMS, PMDD, or postnatal depression are significantly more likely to experience severe psychological symptoms during perimenopause.

Surgical menopause: Women who undergo bilateral oophorectomy (removal of both ovaries) experience an abrupt, complete loss of ovarian hormones rather than the gradual transition of natural menopause. This sudden hormonal deprivation produces more severe psychological symptoms than natural menopause in many women, and is a significant risk factor for depression, anxiety, and cognitive decline.

Early or premature menopause: Women who reach menopause before 45-40 face a longer period of oestrogen deficiency with correspondingly greater psychological impact.

Stressful life circumstances: Perimenopause frequently coincides with significant life stressors – aging parents, children leaving home, relationship changes, career transitions – that interact with the neurobiological vulnerability of the transition.

Sleep deprivation: Women with severe night sweats and disrupted sleep have worse mental health outcomes during perimenopause – the sleep-mood relationship is bidirectional and powerful.

Treatment

HRT for Mental Health

This is the most important message for perimenopausal women with mental health symptoms: oestrogen therapy has evidence for improving mood, anxiety, and cognitive symptoms in perimenopause – and for many women, it should be tried before or alongside antidepressants.

Multiple randomised controlled trials have demonstrated that oestrogen therapy has antidepressant effects in perimenopausal (but not postmenopausal) depression. A landmark 2018 trial by Gordon et al. found that transdermal oestradiol significantly reduced depressive symptoms in perimenopausal women compared to placebo.

HRT also improves anxiety symptoms, sleep (by treating night sweats and having direct effects on sleep architecture), and cognitive symptoms. The cognitive benefit of HRT during the perimenopause transition is an active area of research, with growing evidence that early initiation may protect brain health long-term.

The implication: A woman in perimenopause presenting with new anxiety, depression, or cognitive symptoms deserves a conversation about HRT – not an automatic prescription for antidepressants. For many perimenopausal women, treating the underlying hormonal cause produces greater and more complete improvement than treating the downstream psychiatric symptoms.

Antidepressants

Antidepressants are appropriate when:

• HRT is contraindicated
• The woman prefers not to use HRT
• Mood symptoms are severe and require rapid treatment
• Symptoms persist despite adequate HRT

SSRIs and SNRIs are the most used. SSRIs (escitalopram, sertraline) work well for anxiety and depression. SNRIs (venlafaxine, desvenlafaxine) also reduce vasomotor symptoms – a dual benefit in perimenopausal women.

Cognitive Behavioural Therapy (CBT)

CBT has strong evidence for perimenopausal mental health specifically:

• CBT for menopausal symptoms significantly reduces the distress associated with hot flushes, improving quality of life even without changing flush frequency
• CBT for insomnia (CBT-I) is the gold-standard treatment for sleep disruption in menopause
• Standard CBT for anxiety and depression is appropriate for psychological symptoms

Mindfulness-Based Approaches

Mindfulness-based stress reduction (MBSR) and mindfulness-based cognitive therapy (MBCT) have evidence for reducing anxiety, depression, and the distress associated with menopausal symptoms.

Exercise

Regular aerobic exercise improves mood, anxiety, sleep quality, and cognitive function in perimenopausal women. It also reduces vasomotor symptom severity and improves body image and self-efficacy. The mental health benefits of exercise in menopause are consistent across multiple studies.

Sleep Management

Treating the underlying causes of sleep disruption (particularly night sweats with HRT or non-hormonal options) combined with CBT-I produces the most effective improvement in sleep quality, with downstream benefits for mood and cognition.

Frequently Asked Questions

I’ve been put on antidepressants for anxiety but I’m in my late 40s and haven’t been anxious before. Could this be perimenopause? Yes – this is one of the most common scenarios in perimenopausal mental health mismanagement. New-onset anxiety in the mid-to-late 40s, particularly if accompanied by sleep disturbance, irregular periods, or any physical symptoms like palpitations or joint pain, should prompt consideration of perimenopause. A knowledgeable healthcare provider can assess this clinically. HRT may be more appropriate than antidepressants as first-line treatment for hormonal anxiety.

Will my mental health improve after menopause is complete? For most women – yes. The most severe mental health symptoms of the menopausal transition typically relate to the hormonal fluctuations of perimenopause rather than to oestrogen deficiency alone. Once hormone levels stabilise postmenopause, mood usually improves. However, postmenopausal oestrogen deficiency can still contribute to mood and cognitive symptoms, and HRT continues to benefit those who need it.

Can menopause cause suicidal thoughts? Severe perimenopausal depression can include suicidal ideation, and women in perimenopause represent a high-risk group for suicide that is underrecognised in public health discussions. If you are experiencing thoughts of suicide or self-harm, please seek urgent help from a mental health professional or emergency services. This is a medical emergency that requires immediate treatment, not waiting.

Is brain fog a sign of early dementia? Almost certainly not in perimenopausal women. The cognitive changes of perimenopause – word-finding difficulties, memory lapses, brain fog – are well-documented, largely reversible changes driven by hormonal transition. Research consistently shows that cognitive function returns to baseline after the transition. Dementia has a distinct clinical presentation and progression. If cognitive changes are severe, progressive, or accompanied by other concerning neurological symptoms, evaluation is appropriate – but for most perimenopausal women with brain fog, hormonal management is the appropriate response.

Should I tell my employer about perimenopausal mental health symptoms? This is a personal decision. Many women find that their perimenopausal symptoms significantly affect their work performance – and increasingly, menopause policies in workplaces are recognising this. In many countries, employers have legal obligations to make reasonable adjustments for health conditions including menopause. Occupational health departments can provide confidential support. The decision to disclose is yours – but support is available.

Disclaimer

This article is for educational purposes only and does not constitute medical advice or mental health advice. If you are experiencing severe depression, anxiety, or thoughts of self-harm, please seek immediate help from a healthcare professional or emergency services. Mental health treatment during menopause should be individualised with a qualified provider.

References

1. Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler SS. Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition. JAMA Psychiatry. 2018;75(2):149-157. https://doi.org/10.1001/jamapsychiatry.2017.3998
2. Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Archives of General Psychiatry. 2004;61(1):62-70. https://doi.org/10.1001/archpsyc.61.1.62
3. Bromberger JT, Kravitz HM. Mood and menopause: findings from the Study of Women’s Health Across the Nation (SWAN) over 10 years. Obstetrics and Gynecology Clinics of North America. 2011;38(3):609-625. https://doi.org/10.1016/j.ogc.2011.05.011
4. Maki PM, Kornstein SG, Joffe H, et al. Guidelines for the evaluation and treatment of perimenopausal depression. Menopause. 2018;25(10):1069-1085. https://doi.org/10.1097/GME.0000000000001174
5. Greendale GA, Karlamangla AS, Maki PM. The menopause transition and cognition. JAMA. 2020;323(15):1495-1496. https://doi.org/10.1001/jama.2020.1757
6. NICE (National Institute for Health and Care Excellence). Menopause: diagnosis and management. 2015 (updated 2019). https://www.nice.org.uk/guidance/ng23
7. British Menopause Society. Menopause and mental health. https://thebms.org.uk
8. Hunter MS, Ayers B, Smith M. The hot flush behaviour scale: a measure of behavioural reactions to menopausal hot flushes and night sweats. Menopause. 2011;18(11):1178-1183. https://doi.org/10.1097/gme.0b013e31821f7a13
9. Soares CN. Depression and menopause: current knowledge and clinical recommendations for a critical window. Psychiatric Clinics of North America. 2017;40(2):239-254. https://doi.org/10.1016/j.psc.2017.01.007
10. World Health Organization (WHO). Mental health of women. https://www.who.int/news-room/fact-sheets/detail/mental-health-of-women